Phase I, multiple ascending dose trial of XP 23829 and dimethyl fumarate in volunteers.

Trial Profile

Phase I, multiple ascending dose trial of XP 23829 and dimethyl fumarate in volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2014

At a glance

  • Drugs XP 23829 (Primary) ; Dimethyl fumarate
  • Indications Multiple sclerosis; Psoriasis
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 08 Nov 2013 Additional results were published in a XenoPort media release.
    • 09 Sep 2013 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top